Welcome to our dedicated page for Ibio SEC filings (Ticker: IBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
iBio, Inc. filings document material events for an AI-driven biotechnology company developing precision antibody therapies. Recent Form 8-K disclosures cover clinical and regulatory updates for IBIO-600, preclinical data for IBIO-610, quarterly financial results, Regulation FD communications and other pipeline-related events.
The company's filings also record capital-structure matters involving common stock, pre-funded warrants and Series G warrants, along with shareholder voting results, board composition, committee appointments and governance items disclosed through annual-meeting and material-event reports.
iBio, Inc. is registering 11,061,738 shares of common stock for resale by existing investors following a January 2026 private placement. The shares include 1,408,481 already issued common shares and up to 9,653,257 shares issuable upon exercise of pre-funded warrants with a $0.001 exercise price.
The company previously raised approximately $26 million in gross proceeds in the private placement at a purchase price of $2.35 per common share. iBio will not receive proceeds from resale of these shares, other than nominal amounts if the pre-funded warrants are exercised. The filing fulfills registration rights granted to the investors and may increase potential share sales into the market.
iBio, Inc. reported that its Chief Legal Officer, Marc Banjak, received a grant of stock options on January 28, 2026. The award covers 146,000 stock options with an exercise price of $2.23 per share, all held directly.
According to the vesting terms, 25% of the common stock underlying these options will vest on the one-year anniversary of the grant date. The remaining options will then vest in equal quarterly installments over the following 36 months, so long as Banjak remains employed by iBio.
iBio, Inc. reported that its Chief Financial Officer, Felipe Duran, received a grant of stock options covering 179,000 shares of common stock on January 28, 2026 at an exercise price of $2.23 per share. All 179,000 options were reported as directly owned after the grant.
The options vest over time. 25% of the underlying shares will vest on the one-year anniversary of the grant date, and the remaining options will vest in equal quarterly installments over the following 36 months, as long as Duran remains employed by iBio. The options become exercisable starting January 28, 2027 and are scheduled to expire on January 27, 2036.
iBio, Inc. reported that its Chief Executive Officer and Chief Scientific Officer, Martin Brenner, who also serves as a director, received a grant of stock options. On January 28, 2026, he was awarded 479,000 stock options to purchase common stock at an exercise price of $2.23 per share.
According to the filing, 25% of the underlying shares will vest on the one-year anniversary of the grant date. The remaining 75% will vest in equal quarterly installments over the following 36 months, as long as Brenner remains employed by iBio. After this grant, he beneficially owns 479,000 stock options directly.
Affinity Asset Advisors, LLC and Michael Cho report a 9.99% beneficial stake in iBio, Inc. common stock. They collectively report control over 2,401,616 shares, including 144,416 shares issuable upon exercise of warrants.
The securities are held through Affinity Healthcare Fund, LP, for which Affinity Asset Advisors acts as investment manager. The warrants are subject to a 9.99% beneficial ownership limitation, and the position is certified as being held in the ordinary course of business, not to influence control of iBio.
iBio, Inc. received a Schedule 13G filing from several Millennium-affiliated investment entities and Israel A. Englander disclosing a new passive ownership position. Integrated Core Strategies (US) LLC reports beneficial ownership of 1,234,295 shares of iBio common stock, while Millennium Management LLC, Millennium Group Management LLC and Mr. Englander each report 1,235,827 shares, representing 5.2% of the outstanding common stock in each case.
The ownership percentage is based on 23,895,789 iBio shares outstanding, combining 22,487,308 shares reported in a prior Form 10‑Q/A and 1,408,481 shares issued in a recent private placement. The reporting persons certify the shares were not acquired and are not held for the purpose of changing or influencing control of iBio, and they entered into a joint filing agreement to report this position together.
iBio, Inc. entered into a securities purchase agreement with institutional investors for a private placement priced at-the-market, raising approximately $26 million in gross proceeds. The company agreed to sell 1,408,481 shares of common stock at $2.35 per share and issue pre-funded warrants to purchase up to 9,653,257 additional shares at an exercise price of $0.001 per share, with a purchase price of $2.349 per pre-funded warrant.
The closing is expected on or about January 13, 2026, and iBio plans to use the net proceeds to advance its preclinical cardiometabolic pipeline, including IBIO-610, IBIO-600 and myostatin/activin A bispecific programs, as well as other preclinical assets, and for working capital and general corporate purposes. The company granted investors registration rights for resale of the shares and warrant shares and agreed to temporary restrictions on additional equity issuances and certain corporate actions until the resale registration statement becomes effective or 60 days after closing.
iBio, Inc. reported a stock option grant to a director on a Form 4. On 11/20/2025, the director received 13,500 stock options with an exercise price of $1 per share, expiring on 11/19/2035. These options vest pro rata on a monthly basis over twelve months starting on the grant date. Following this transaction, the director beneficially owns 13,500 derivative securities, held as a direct ownership position.
iBio, Inc. (IBIO) reported a routine insider equity grant on a Form 4. A company director received a stock option (right to buy) covering 13,500 shares of common stock on 11/20/2025 with an exercise price of $1 per share. The option expires on 11/19/2035, giving a long window to purchase shares at that price. These options vest on a pro rata monthly basis over twelve months starting from the grant date, meaning the director earns the right to exercise a portion of the option each month during the first year.
iBio, Inc. (IBIO) reported a director equity award on a Form 4. On 11/20/2025, the reporting person received a stock option grant covering 13,500 shares of iBio common stock. The options have an exercise price of $1 per share and an expiration date of 11/19/2035.
The filing states that these options vest on a pro rata basis each month over twelve months, starting on the grant date. Following this grant, the reporting person beneficially owns 13,500 derivative securities directly in the form of these options.